[1]
F. Ehret, “The IDEAL trial - a study protocol for a phase III randomized, double-blinded clinical trial assessing the ultra-short antibiotic prophylaxis of Isoniazid and Rifapentine in non-immunosuppressed patients with newly diagnosed latent tuberculosis”, PPCR, vol. 6, no. 1, pp. 9–14, May 2020.